help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kampe, O.
Right arrow Articles by Karlsson, F. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kampe, O.
Right arrow Articles by Karlsson, F. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*High Risk Pregnancy
Hazardous Substances DB
*IODINE
*LEVOTHYROXINE

Journal of Clinical Endocrinology & Metabolism, Vol 70, 1014-1018, Copyright © 1990 by Endocrine Society


ARTICLES

Effects of L-thyroxine and iodide on the development of autoimmune postpartum thyroiditis

O Kampe, R Jansson and FA Karlsson
Department of Internal Medicine, University Hospital, Uppsala, Sweden.

In the present study we examined the influence of L-T4 and iodide on autoimmune postpartum thyroiditis. Women at risk of developing the disease were identified in early pregnancy by the presence of moderate or high titers of antibodies against thyroid peroxidase (TPOAb). They were given no treatment (n = 20), 0.1 mg L-T4 daily (n = 18), or 0.15 mg iodide daily (n = 20) for 40 weeks postpartum. Changes in thyroid function were seen in all women, although in nine hormone values remained within the reference ranges of erthymoid individuals. In each group of women, thyrotoxicosis occurred around 2-3 months postpartum, followed by a gradual rise of TPOAb. Subsequently, around 5-7 months postpartum, a hypothyroid phase was observed. TSH elevations (greater than 5 mU/L) occurred in 9 of 18 women in spite of treatment with 0.1 mg L-T4 although elevations were lower than in the other two groups. Among those women who developed abnormal thyroid function, the hormone changes appeared greater in the iodide-treated group than in the control group, suggesting that in certain patients iodide may aggravate rather than ameliorate the disease. All 58 women showed a reduction of TPOAb during pregnancy and a transient rise during the postpartum year. The extent of TPOAb elevations did not differ between the groups. Thus, the administration of L-T4 prevented hypothyroid symptoms, but did not alter the course of the postpartum thyroiditis, which appears not to be accelerated by events of target cell origin.


This article has been cited by other articles:


Home page
Endocr. Rev.Home page
A. F. Muller, H. A. Drexhage, and A. Berghout
Postpartum Thyroiditis and Autoimmune Thyroiditis in Women of Childbearing Age: Recent Insights and Consequences for Antenatal and Postnatal Care
Endocr. Rev., October 1, 2001; 22(5): 605 - 630.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. B. Nøhr, A. Jørgensen, K. M. Pedersen, and P. Laurberg
Postpartum Thyroid Dysfunction in Pregnant Thyroid Peroxidase Antibody-Positive Women Living in an Area with Mild to Moderate Iodine Deficiency: Is Iodine Supplementation Safe?
J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3191 - 3198.
[Abstract] [Full Text]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Stagnaro-Green
Postpartum Thyroiditis: The Case For Selective Screening
J. Clin. Endocrinol. Metab., June 1, 1999; 84(6): 1819 - 1821.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1990 by The Endocrine Society